Patents by Inventor Philip E. Hass

Philip E. Hass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 11725050
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: August 15, 2023
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20230063741
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: April 15, 2022
    Publication date: March 2, 2023
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20220213184
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: July 12, 2021
    Publication date: July 7, 2022
    Inventors: David P. Arnott, Austin L. Gurney, Philip E. Hass, James M. Lee, Yan Wu
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20220213183
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: July 12, 2021
    Publication date: July 7, 2022
    Inventors: David P Arnott, Austin L. Gurney, Philip E. Hass, James M. Lee, Yan Wu
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20220204606
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: July 12, 2021
    Publication date: June 30, 2022
    Inventors: David P Arnott, Mercedesz Balazs, Nico Ghilardi, Austin L. Gurney, Philip E. Hass, Sarah Hymowitz, James M. Lee, Wenjun Ouyang, Melissa A. Starovasnik, Yan Wu
  • IL-22 Fc fusion proteins
    Patent number: 11332507
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 17, 2022
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • TIE2-BINDING AGENTS AND METHODS OF USE
    Publication number: 20210332142
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Application
    Filed: March 22, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Minhong YAN, Gu ZHANG, Nicholas John AGARD, Danielle Marie DICARA, Philip E. HASS, Julie Q. HANG, Erin L. CHRISTENSEN, Robert Paul MORSE, Sarah SANOWAR, Vittal SHIVVA
  • Methods of treating acute pancreatitis using IL-22 fc fusion proteins
    Patent number: 11155591
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Eric Gary Stefanich, Richard Vandlen, Philip E. Hass, Xiaoting Wang
  • Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins
    Patent number: 11136365
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 5, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen
  • Methods for treating metabolic syndrome using IL-22 Fc fusion proteins
    Patent number: 11130791
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Eric Gary Stefanich, Richard Vandlen, Philip E. Hass, Xiaoting Wang
  • Anti-factor D antibody variant conjugates and uses thereof
    Patent number: 10961313
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: March 30, 2021
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF
    Publication number: 20210002361
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Application
    Filed: June 16, 2020
    Publication date: January 7, 2021
    Inventors: Philip E. HASS, Meredith HAZEN, Yi-Chun HSIAO, Rajita KHOSLA, Gerald R. NAKAMURA, Dhaya SESHASAYEE, Menno VAN LOOKEREN CAMPAGNE, Hongkang XI, Wenwu ZHAI, Jack BEVERS, III, Nancy CHIANG
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20200385452
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: December 2, 2019
    Publication date: December 10, 2020
    Applicant: Genentech, Inc.
    Inventors: David P. ARNOTT, Austin L. GURNEY, Philip E. HASS, James M. LEE, Yan WU
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20200377584
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: January 7, 2020
    Publication date: December 3, 2020
    Inventors: David P. ARNOTT, Austin L. GURNEY, Philip E. HASS, James M. LEE, Yan WU
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20200377585
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: February 6, 2020
    Publication date: December 3, 2020
    Applicant: Genentech, Inc.
    Inventors: David P. ARNOTT, Mercedesz BALAZS, Nico GHILARDI, Austin L. GURNEY, Philip E. HASS, Sarah HYMOWITZ, James M. LEE, Wenjun OUYANG, Melissa A. STAROVASNIK, Yan WU
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 10723795
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: July 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • Anti-factor D antibody variant conjugates and uses thereof
    Patent number: 10654932
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • ANTI-FACTOR D ANTIBODY VARIANT CONJUGATES AND USES THEREOF
    Publication number: 20200115462
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Application
    Filed: December 30, 2019
    Publication date: April 16, 2020
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • Pharmaceutical compositions of IL-22 Fc fusion proteins
    Patent number: 10584155
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 10, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • Methods of accelerating or improving wound healing using IL-22 FC fusion proteins
    Patent number: 10544198
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang, Ganesh A. Kolumam, Wyne P. Lee